New PCSK9 Inhibitor Allows 3-Month Treatment Intervals
This site is intended for healthcare professionals

New PCSK9 Inhibitor Allows 3-Month Treatment Intervals

Richard Mark Kirkner

November 29, 2023

0

PHILADELPHIA – An investigational PCSK9 inhibitor that can be injected every 1-3 months as add-on therapy for patients with stubbornly high low-density lipoprotein (LDL) cholesterol has demonstrated cholesterol lowering for up to a year, in a clinical trial.

The results are from the phase 3 Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia (REMAIN-2) trial.

Dr Xin Du

"It's a new antibody that has a long half-life so each treatment can be prolonged," investigator Xin Du, MD, professor of cardiology at Beijing Anzhen Hospital and the Capital Medical University, said in an interview. "Previous drugs like alirocumab and evolocumab have to be given every 2 weeks or every 4 weeks, and this new drug can be given even every 12 weeks, so it can get a very strong effect of LDL cholesterol lowering even when given every 3 months."

Recaticimab has demonstrated a half-life of 18.6 to 27.4 days vs. 11 to 17 days for alirocumab and evolocumab, she said.

"Currently a high proportion of patients prescribed the PCSK9 inhibitors withdraw from therapy," Dr. Du said. "After 36 months, only half of them are still on that therapy."

Dr. Du presented the trial results at the annual scientific sessions of the American Heart Association.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....